Physician profile
Refat Baridi
NPI 1285622621
$6,188.09
in general payments reported to CMS, 2019-2025
53 companies · $1,572 in 2025
The $1,572 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $218 · 2020: $231 · 2021: $382 · 2022: $714 · 2023: $1,552 · 2024: $1,519 · 2025: $1,572.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,474 · Education: $169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,474.14 |
| Education | $168.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $522.77 | 2021-2025 | Lynparza, Enhertu, Imfinzi |
| Novartis Pharmaceuticals Corporation | $385.34 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $383.27 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $347.58 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $313.79 | 2021-2025 | Opdivo, Eliquis, Opdualag |
| Lilly USA, LLC | $254.45 | 2021-2024 | Verzenio, Retevmo, Jaypirca |
| Celgene Corporation | $244.18 | 2021-2025 | Reblozyl, Pomalyst |
| Takeda Pharmaceuticals U.S.A., INC. | $235.16 | 2022-2025 | Ninlaro, Alunbrig, Fruzaqla |
| Janssen Biotech, INC. | $216.77 | 2019-2025 | Rybrevant, Tecvayli, Darzalex |
| Glaxosmithkline, LLC. | $210.57 | 2022-2025 | Jemperli, Zejula, Ojjaara |
| Gilead Sciences, INC. | $197.79 | 2021-2025 | Trodelvy |
| Amgen INC. | $185.50 | 2019-2023 | Vectibix, Xgeva, Nplate |
| Regeneron Healthcare Solutions, INC. | $181.49 | 2022-2024 | Libtayo |
| Eisai INC. | $146.70 | 2023-2024 | |
| Astellas Pharma US INC | $142.28 | 2023-2025 | Padcev, Xtandi |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $140.22 | 2022-2025 | Enhertu |
| Incyte Corporation | $135.75 | 2022-2025 | Jakafi |
| Amag Pharmaceuticals, INC. | $116.87 | 2021 | |
| Genentech USA, INC. | $115.08 | 2021-2025 | Polivy, Tecentriq, Avastin |
| Beigene USA, INC. | $102.60 | 2023-2025 | Brukinsa |
| Amneal Pharmaceuticals LLC | $97.53 | 2023-2025 | Avastin, Alymsys |
| Mirati Therapeutics, INC. | $91.86 | 2023-2024 | Krazati |
| Abbvie INC. | $85.40 | 2023-2025 | Venclexta |
| Tersera Therapeutics LLC | $80.40 | 2025 | Zoladex, Xermelo |
| Aveo Pharmaceuticals, INC. | $74.77 | 2024-2025 | |
| Morphosys, US INC. | $73.36 | 2022-2024 | Monjuvi |
| Celltrion USA INC. | $70.54 | 2023-2025 | Vegzelma |
| Global Blood Therapeutics, INC. | $68.34 | 2020 | |
| Karyopharm Therapeutics INC. | $67.47 | 2020-2025 | Xpovio |
| Seagen INC. | $66.31 | 2020-2023 | Padcev |
| Genzyme Corporation | $65.81 | 2023-2025 | |
| Fresenius Kabi USA, LLC | $62.55 | 2023-2025 | Stimufend |
| Deciphera Pharmaceuticals INC. | $60.02 | 2021-2025 | Qinlock, Romvimza |
| Jazz Pharmaceuticals INC. | $57.12 | 2023-2024 | |
| Puma Biotechnology, INC. | $50.19 | 2023-2024 | |
| Sumitomo Pharma America, INC. | $49.56 | 2023-2025 | Orgovyx |
| Alexion Pharmaceuticals, INC. | $48.87 | 2024-2025 | Ultomiris |
| Bayer Healthcare Pharmaceuticals INC. | $48.04 | 2023 | |
| Coherus Oncology, INC. | $45.49 | 2020-2024 | |
| Pharmacosmos Therapeutics INC. | $42.36 | 2024 | Cosela |
| Array Biopharma INC | $38.50 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Stemline Therapeutics INC. | $35.20 | 2024-2025 | Orserdu |
| Inspire Medical Systems, INC. | $31.24 | 2024 | Inspire |
| Servier Pharmaceuticals LLC | $23.86 | 2023 | |
| Dova Pharmaceuticals | $23.65 | 2020 | |
| Myriad Genetic Laboratories, INC. | $23.63 | 2023 | Myrisk |
| G1 Therapeutics, INC. | $23.11 | 2023 | Cosela |
| Adc Therapeutics America, INC. | $22.14 | 2022 | |
| Fennec Pharmaceuticals, INC. | $20.36 | 2024 | Pedmark |
| Exelixis INC. | $19.04 | 2022 | |
| Immunocore Limited | $17.12 | 2025 | Kimmtrak |
| Coopersurgical, INC. | $13.20 | 2021 | |
| Kite Pharma, INC. | $12.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Refat Baridi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.